Premier Research appoints Anthony Orlando and Bruce C. Stouch to New Senior Management Positions
Premier Research Group plc (AIM: PRG) ("Premier ResearchÅh, ÅgCompany" or ÅgGroupÅh), the international pharmaceutical services group today announces the appointment of Anthony Orlando, Ph.D. and Bruce C. Stouch, Ph.D. to senior management positions in Premier Research.
PHILADELPHIA, May 10 -- Premier Research Group plc (AIM: PRG) ("Premier Research," "Company" or "Group), the international pharmaceutical services group today announces the appointment of -- Anthony Orlando, Ph.D. and Bruce C. Stouch, Ph.D. to senior management positions in Premier Research.
Dr Anthony Orlando, Ph.D. has joined the US Operations of Premier Research Group plc in the new position of Executive Director, Data Operations. Dr. Orlando brings an exceptional background in Biostatistics and Data Management over the past thirty years including key roles in pharmaceutical companies, the National Center for Toxicological Research/FDA and at major contract research organizations. He most recently joined the company from his position as Vice President, Biostatistics at SFBC New Drug Services. Dr. Orlando holds a Ph.D. in Biometry from Yale University has co-authored many papers in his area of expertise and has supported several drug NDAs for a variety of indications. He will be responsible for US data management, programming and biostatistics for Premier Research.
In addition to Dr. Orlandofs position, Premier Research also is pleased to announce that Bruce C. Stouch, Ph.D. has taken the international position of Chief Scientific Officer for the company. In Dr. Stouchfs new role, he will lead the company's efforts supporting expert FDA/statistical clinical design and analysis capabilities. He will also establish and expand the companyfs new initiative into Bayesian monitoring and analysis methods. Dr. Stouch has over 15 years of biostatistics experience in pharmaceuticals.
For 12 years, Dr. Stouch held the position of Director of Biostatistics and Scientific Data Management at Johnson & Johnson in Exton, PA, where he was responsible for strategic development and implementation of pharmacoeconomic models of emerging technologies in several therapeutic areas. Dr. Stouch has been involved in over two dozen publications and acknowledgements. He holds an academic appointment at the Philadelphia College of Medicine as Director, Biostatistics and Clinical Epidemiology. Dr. Stouch received his Ph.D. in Biostatistics and Epidemiology from Jefferson Medical College in 1997 through a program sponsored by Johnson & Johnson, and trained in post-graduate studies from Temple University, Jefferson Medical College, and Harvard School of Public Health.
Dr Simon Yaxley, CEO of Premier Research Group plc, commented: gWe are proud and pleased to announce the significant strengthening of our data management and statistics capabilities in the US Operations. We also believe that Tony and Bruce place our company at the forefront of trial design, monitoring and analysis methods worldwide.
About Premier Research
Premier Research Group plc is a contract research organisation focused on the design, management and reporting of all phases of clinical trials on behalf of pharmaceutical and biotechnology companies. The Company specialises in oncology, central nervous system, paediatrics and anti-infectives.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
